![](/img/cover-not-exists.png)
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Assi, Rita, Kantarjian, Hagop M., Kadia, Tapan M., Pemmaraju, Naveen, Jabbour, Elias, Jain, Nitin, Daver, Naval, Estrov, Zeev, Uehara, Taisuke, Owa, Takashi, Cortes, Jorge E., Borthakur, GautamLanguage:
english
Journal:
Cancer
DOI:
10.1002/cncr.31398
Date:
April, 2018
File:
PDF, 525 KB
english, 2018